Duchenne Muscular Dystrophy

DMD is a fatal genetic disease that occurs in approximately 1 in 5,000 males with one third of cases arising in boys with no familial history of the disease.

Our utrophin modulation programme is a potential disease-modifying approach to treat all patients with DMD.

Duchenne Muscular Dystrophy image boy

C. difficile Infection

Infection caused by the bacterium C. difficile is a major healthcare threat in hospitals, long-term care homes, and increasingly in the wider community.

We are developing ridinilazole (SMT19969), a highly selective antibiotic that has the potential to treat CDI and reduce disease recurrence, the key clinical issue.

C. Difficile Infections banner image


We regularly publish data on our drug programmes in peer-reviewed journals and gives presentations at leading international conferences. This section provides access to this information.

UtroDMD Alliance logo